Zynerba Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, ZYNE, Zynerba Pharmaceuticals Inc, priceseries

Zynerba Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
1.87
Close
1.92
High
2.00
Low
1.85
Previous Close
1.90
Daily Price Gain
0.02
YTD High
3.08
YTD High Date
Jan 3, 2022
YTD Low
1.85
YTD Low Date
Mar 7, 2022
YTD Price Change
-1.10
YTD Gain
-36.42%
52 Week High
7.03
52 Week High Date
Mar 15, 2021
52 Week Low
1.85
52 Week Low Date
Mar 7, 2022
52 Week Price Change
-2.22
52 Week Gain
-53.62%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 6. 2017
18.47
Mar 2. 2017
21.51
17 Trading Days
16.45%
Link
LONG
Apr 6. 2017
20.84
Apr 21. 2017
22.92
10 Trading Days
9.99%
Link
LONG
Nov 2. 2017
9.85
Dec 4. 2017
13.18
21 Trading Days
33.82%
Link
LONG
Apr 10. 2018
9.15
Apr 30. 2018
10.33
14 Trading Days
12.87%
Link
LONG
May 25. 2018
10.14
Jun 18. 2018
10.98
15 Trading Days
8.25%
Link
LONG
Aug 27. 2018
6.47
Sep 6. 2018
7.45
7 Trading Days
15.16%
Link
LONG
Jan 29. 2019
4.81
Feb 6. 2019
5.14
6 Trading Days
6.86%
Link
LONG
Apr 2. 2019
6.48
Apr 18. 2019
7.75
12 Trading Days
19.66%
Link
LONG
Apr 22. 2019
9.50
May 2. 2019
10.32
8 Trading Days
8.60%
Link
LONG
May 9. 2019
11.96
May 23. 2019
13.59
10 Trading Days
13.66%
Link
LONG
Jun 28. 2019
13.55
Jul 10. 2019
14.34
7 Trading Days
5.80%
Link
LONG
May 18. 2020
4.89
May 29. 2020
5.29
8 Trading Days
8.13%
Link
LONG
Feb 5. 2021
5.08
Feb 12. 2021
5.34
5 Trading Days
5.07%
Link
Company Information
Stock Symbol
ZYNE
Exchange
NasdaqGM
Company URL
http://zynerba.com
Company Phone
484-581-7505
CEO
Armando Anido
Headquarters
Pennsylvania
Business Address
80 W. LANCASTER AVENUE, SUITE 300, DEVON, PA 19333
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001621443
About

Zynerba Pharmaceuticals, Inc. engages in the research and development of drugs. Its clinical programs include synthetic cannabinoid therapeutics and patch and gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.

Description

Zynerba Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its products candidates include ZYN002, which is in Phase I clinical trial for the treatment of refractory epilepsy, Fragile X syndrome, and osteoarthritis; and ZYN001 that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. The company was founded in 2007 and is headquartered in Devon, Pennsylvania.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading